UPDATE: Bank of America Raises PT to $70 on Baxter International; Gambro Strategic Fit at Steep Price
Bank of America reiterated its Buy rating on Baxter International (NYSE: BAX) and increased its price target from $67 to $70.
Bank of America commented, "On Friday the Wall Street Journal and several other media outlets reported that BAX is in talks to acquire privately held Gambro for $4bn (BAX's market cap is $38bn). Gambro is the #2 share player in the hemodialysis technology market where BAX has little presence, and BAX is #1 in the peritoneal dialysis market where Gambro has no presence. In our view, in the hands of BAX, Gambro would be a much tougher HD competitor and a strong strategic fit, with the potential for significant synergies, but a $4bn price tag creates a very high hurdle for positive returns in our view."
Baxter International closed at $67.18 on Friday.
Latest Ratings for BAX
|May 2016||Evercore ISI Group||Initiates Coverage on||Buy|
|Apr 2016||Credit Suisse||Maintains||Neutral|
|Apr 2016||Piper Jaffray||Upgrades||Neutral||Overweight|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.